Gliser, Camelia
Agios Pharmaceuticals (United States)
3 papers on CoChatORCID 0009-0006-0044-843X
Most cited papers
- Verified
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science
Acute Myeloid Leukemia ResearchCancer, Hypoxia, and Metabolism
Cited by 804
- Verified
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
Tap, W. D., Villalobos, V. M., Cote, G. M., Burris, H., Janku, F., Mir, O., Beeram, M., Wagner, A. J., Jiang, L., Wu, B., et al. (2020) · Journal of Clinical Oncology
Bone Tumor Diagnosis and TreatmentsSarcoma Diagnosis and Treatment
Cited by 165
- Verified
Mutant IDH is sufficient to initiate enchondromatosis in mice
Hirata, M., Sasaki, M., Cairns, R. A., Inoue, S., Puviindran, V., Li, W. Y., Snow, B. E., Jones, L. D., Wei, Q., Sato, S., et al. (2015) · Proceedings of the National Academy of Sciences
Bone Tumor Diagnosis and TreatmentsOsteoarthritis Treatment and Mechanisms
Cited by 115
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free